Please login to the form below

Not currently logged in
Email:
Password:

Caldan Therapeutics appoints CEO

Dr Mark Payton joins the Universities of Glasgow and Southern Denmark spin-out

Caldan Therapeutics Dr Mark PaytonEdinburgh, UK-based Caldan Therapeutics has appointed Dr Mark Payton as chief executive officer.

Dr Payton joins the metabolic disease specialist - a spin-out company from the Universities of Glasgow and Southern Denmark - from MAPBiotech, where he has served as chief executive officer since 2014.

Prior to this, Dr Payton has been chief executive officer of both Atopix Therapeutics and Oxagen, both based in Oxfordshire, UK, and brings further industry experience from GlaxoSmithKline and Biogen.

He co-founded autoimmune disease-focused Orca Pharmaceuticals in 2012, and currently also serves as a senior advisor to The Harrington Project for Discovery and Development.

Dr Liz Roper, partner at Epidarex Capital, which backs Caldan Therapeutics, said: “We are delighted to welcome Mark on board to lead Caldan Therapeutics moving forward.

“Continuing to build a strong management team with experienced and talented executives is crucial to building on the science of Professors Milligan and Ulven to deliver new drugs for metabolic diseases.”

8th March 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics